Bayer's two-year-old digital health collaboration ... one-on-one coaching and heart health advice – all delivered and organised via an app. The first iteration of the software is aimed at ...

Bayer plans to launch Acoramidis, a treatment for a rare heart disease called transthyretin amyloid cardiomyopathy, near the end of the first quarter, as well as elinzanetant, a non-hormonal ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...

Bayer has submitted a supplemental new drug application (sNDA) for Kerendia (finerenone) to treat patients with heart failure with a left ventricular ejection fraction (LVEF) of ≥40%. Ejection ...

The drug also cut cardiovascular outcomes – including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or hospitalisation for heart failure – by 14%.